Aortic Disease Clinical Trials

As a patient at Cedars-Sinai, you will have access to the latest clinical trials and research for aortic disease. Backed by a respected team of specialists and researchers, our clinical trials aim to further the advancement of diagnosing and treating your condition.

Questions? See the Clinical Trials FAQs.

Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 2) (SSB 11-02)

Condition: 

Aortic Aneurysm, Thoracic
Aorta; Lesion

Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis (EARLY TAVR)

Condition: 

Aortic Stenosis, Heart Diseases

Evaluation of Valiant Mona LSA

Condition:

Aortic Aneurysm, Thoracic, Chronic Type B Dissection

Condition: 

Aortic stenosis

Key Inclusion Criteria:

  • At least 60 years old
  • Between one month and five years following transcatheter aortic valve replacement or surgical bioprosthetic aortic valve replacement

Summary:

This study focuses on patients who have undergone a transcatheter aortic valve replacement (TAVR) or surgical bioprosthetic aortic valve replacement as part of standard of care. The narrowing of the main outlet valve of the heart (aortic stenosis) due to a build-up of calcium deposits is a common form of heart valve disease. Recently, the TAVR procedure has been developed to replace the aortic valve with a bioprosthetic tissue valve using a minimally invasive technique. The purpose of this study is to determine whether a combined positron emission tomography and computed tomography (PET-CT) heart scan using a radioactive tracer, sodium fluoride, can provide information regarding the durability of valves replaced using the TAVR procedure and conventionally placed valves. The use of sodium fluoride in this study is investigational.

Condition: 

Aortic stenosis, heart failure, aortic insufficiency

Key Inclusion Criteria:

  • New York Heart Association Class ≥2
  • NT-proBNP >1500 pg/mL (or BNP >400 pg/mL) or hospitalization for heart failure within the last year
  • Under appropriate guideline-directed heart failure therapy for a minimum of three months

Summary:

This study focuses on patients with heart failure (HF) who have moderate aortic stenosis (AS). The purpose of the study is to compare the safety and effectiveness of transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 transcatheter heart valve (THV) and optimal heart failure therapy (OHFT) versus OHFT alone in HF patients with moderate AS. OHFT is defined as guideline-directed medical therapy (medication only or a combination of medical therapy and approved heart failure devices).

Zenith® Dissection Clinical Trial

Condition: 

Aortic Dissection